866-997-4948(US-Canada Toll Free)

Bladder Cancer - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Aug 2013

Category :

Bladder Cancer

No. of Pages : 184 Pages

 

Global Markets Directs, \'Bladder Cancer Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Bladder Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bladder Cancer. Bladder Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

 

  • A snapshot of the global therapeutic scenario for Bladder Cancer.
  • A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Bladder Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

 

Reasons to buy

 

  • Identify and understand important and diverse types of therapeutics under development for Bladder Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents


Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Bladder Cancer Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Bladder Cancer 9
Bladder Cancer Therapeutics under Development by Companies 11
Bladder Cancer Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Bladder Cancer Therapeutics - Products under Development by Companies 19
Bladder Cancer Therapeutics - Products under Investigation by Universities/Institutes 21
Companies Involved in Bladder Cancer Therapeutics Development 22
Shionogi & Co., Ltd. 22
Eli Lilly and Company 23
Viralytics Ltd. 24
GlaxoSmithKline plc 25
Seattle Genetics, Inc. 26
Bioniche Life Sciences, Inc. 27
Bavarian Nordic A/S 28
Biotest AG 29
Samyang Corporation 30
Eisai Co., Ltd. 31
MDRNA, Inc. 32
Taiho Pharmaceutical Co., Ltd. 33
Advaxis, Inc. 34
AEterna Zentaris Inc. 35
Alnylam Pharmaceuticals, Inc 36
Oncogenex Pharmaceuticals, Inc. 37
Sanochemia Pharmazeutika AG 38
PharmaGap Inc. 39
Quest PharmaTech Inc. 40
Med Discovery SA 41
Altor BioScience Corporation 42
Telormedix SA 43
Gene Signal International SA. 44
Heat Biologics, Inc. 45
MacroGenics, Inc. 46
Innate Therapeutics Limited 47
Stemline Therapeutics, Inc. 48
BioCancell Therapeutics, Inc. 49
AndroScience Corporation 50
BIND Biosciences, Inc. 51
PharmaMar, S.A. 52
Targa Therapeutics Corp. 53
Cytavis Biopharma GmbH 54
Polaris Group 55
Serometrix, LLC 56
Regulon Inc. 57
Bladder Cancer - Therapeutics Assessment 58
Assessment by Monotherapy Products 58
Assessment by Route of Administration 59
Assessment by Molecule Type 61
Drug Profiles 63
AEZS-108 - Drug Profile 63
apatorsen - Drug Profile 65
MDRG-01 - Drug Profile 67
MDP-01 - Drug Profile 68
paclitaxel-loaded polymeric micelle - Drug Profile 69
ramucirumab - Drug Profile 71
EN-3348 - Drug Profile 75
SL-601 - Drug Profile 77
PVP Hypericin - Drug Profile 78
BT-062 - Drug Profile 79
TMX-202 - Drug Profile 81
BC-819 - Drug Profile 82
BC-821 - Drug Profile 84
MDR-09521 - Drug Profile 85
GAP-107-B-8 - Drug Profile 86
ADXS-HER2 - Drug Profile 88
CVA-21 - Drug Profile 89
SL-052 - Drug Profile 93
MRNA-046 - Drug Profile 95
PM-00104 - Drug Profile 96
aganirsen - Drug Profile 97
docetaxel targeted nanoparticles - Drug Profile 99
Neuregulin-1 - Drug Profile 101
ADI-PEG 20 - Drug Profile 102
GSK-2132231A - Drug Profile 105
margetuximab - Drug Profile 107
celecoxib - Drug Profile 109
MIS-416 - Drug Profile 110
HS-410 - Drug Profile 112
MGA-271 - Drug Profile 113
VEGF/rGel - Drug Profile 114
Revercom - Drug Profile 116
Mobilan - Drug Profile 117
ASC-JM.Z1 - Drug Profile 118
ATX-101 - Drug Profile 119
TDO Inhibitor - Drug Profile 120
SX-MTR1 - Drug Profile 121
LNP-dsP21-322-2\'F - Drug Profile 122
TAS-2985 - Drug Profile 123
Melflufen - Drug Profile 124
DT-310 - Drug Profile 126
DT-320 - Drug Profile 127
DT-330 - Drug Profile 128
nitroxoline - Drug Profile 129
KN-014 - Drug Profile 130
Tyrosine Kinase 3 Inhibitor - Drug Profile 131
Antibody Against Tyrosine Kinase 3 - Drug Profile 132
RNAi Against Tyrosine Kinase 3 - Drug Profile 133
Tyrosine Kinase 3 Soluble Bait - Drug Profile 134
ASG-15ME - Drug Profile 135
Bladder Cancer Therapeutics - Drug Profile Updates 136
Bladder Cancer Therapeutics - Discontinued Products 168
Bladder Cancer Therapeutics - Dormant Products 169
Bladder Cancer - Product Development Milestones 171
Featured News & Press Releases 171


Appendix 179
Methodology 179
Coverage 179
Secondary Research 179
Primary Research 179
Expert Panel Validation 179
Contact Us 180
Disclaimer 180

List of Table


Number of Products Under Development for Bladder Cancer, H2 2013 13
Products under Development for Bladder Cancer - Comparative Analysis, H2 2013 14
Number of Products under Development by Companies, H2 2013 16
Number of Products under Development by Companies, H2 2013 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H2 2013 18
Comparative Analysis by Late Stage Development, H2 2013 19
Comparative Analysis by Mid Clinical Stage Development, H2 2013 20
Comparative Analysis by Early Clinical Stage Development, H2 2013 21
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 22
Products under Development by Companies, H2 2013 23
Products under Development by Companies, H2 2013 (Contd..2) 24
Products under Investigation by Universities/Institutes, H2 2013 25
Shionogi & Co., Ltd., H2 2013 26
Eli Lilly and Company, H2 2013 27
Viralytics Ltd., H2 2013 28
GlaxoSmithKline plc, H2 2013 29
Seattle Genetics, Inc., H2 2013 30
Bioniche Life Sciences, Inc., H2 2013 31
Bavarian Nordic A/S, H2 2013 32
Biotest AG, H2 2013 33
Samyang Corporation, H2 2013 34
Eisai Co., Ltd., H2 2013 35
MDRNA, Inc., H2 2013 36
Taiho Pharmaceutical Co., Ltd., H2 2013 37
Advaxis, Inc., H2 2013 38
AEterna Zentaris Inc., H2 2013 39
Alnylam Pharmaceuticals, Inc, H2 2013 40
Oncogenex Pharmaceuticals, Inc., H2 2013 41
Sanochemia Pharmazeutika AG, H2 2013 42
PharmaGap Inc., H2 2013 43
Quest PharmaTech Inc., H2 2013 44
Med Discovery SA, H2 2013 45
Altor BioScience Corporation, H2 2013 46
Telormedix SA, H2 2013 47
Gene Signal International SA., H2 2013 48
Heat Biologics, Inc., H2 2013 49
MacroGenics, Inc., H2 2013 50
Innate Therapeutics Limited, H2 2013 51
Stemline Therapeutics, Inc., H2 2013 52
BioCancell Therapeutics, Inc., H2 2013 53
AndroScience Corporation, H2 2013 54
BIND Biosciences, Inc., H2 2013 55
PharmaMar, S.A., H2 2013 56
Targa Therapeutics Corp., H2 2013 57
Cytavis Biopharma GmbH, H2 2013 58
Polaris Group, H2 2013 59
Serometrix, LLC, H2 2013 60
Regulon Inc., H2 2013 61
Assessment by Monotherapy Products, H2 2013 62
Assessment by Stage and Route of Administration, H2 2013 64
Assessment by Stage and Molecule Type, H2 2013 66
Bladder Cancer Therapeutics - Drug Profile Updates 140
Bladder Cancer Therapeutics - Discontinued Products 172
Bladder Cancer Therapeutics - Dormant Products 173
Bladder Cancer Therapeutics - Dormant Products (Contd..1) 174

List of Chart


Number of Products under Development for Bladder Cancer, H2 2013 13
Products under Development for Bladder Cancer - Comparative Analysis, H2 2013 14
Products under Development by Companies, H2 2013 15
Products under Investigation by Universities/Institutes, H2 2013 18
Late Stage Products, H2 2013 19
Mid Clinical Stage Products, H2 2013 20
Early Clinical Stage Products, H2 2013 21
Discovery and Pre-Clinical Stage Products, H2 2013 22
Assessment by Monotherapy Products, H2 2013 62
Assessment by Route of Administration, H2 2013 63
Assessment by Stage and Route of Administration, H2 2013 64
Assessment by Molecule Type, H2 2013 65
Assessment by Stage and Molecule Type, H2 2013 66

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *